本帖最后由 老马 于 2012-1-13 21:20 编辑
$ }7 d, g$ H6 I% j. F3 B- @- i7 P3 a( K. Y. d& ?
爱必妥和阿瓦斯丁的比较3 j3 Q- Z2 {. y+ }* E9 F
% D0 K0 z1 \( ~$ u
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
* M# `/ Y, m% X8 C8 r
6 C. E" C; v% U
" P. o' o) d" V# ^* k& D
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/0 Z, F. R( j- }8 O6 v
==================================================
& G0 e) Q9 ]* JOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)0 a4 V+ O6 [8 w5 r& n' O {$ D7 I) E! Q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.6 @0 [! E: T3 \* f* @2 w
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
/ O5 r" f$ k. G( Y& h% v$ }: m( `
|